Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Collaborations
Pharmaceutical companies agree to collaborate on phase 3 ADHD drug candidate
March 3rd, 2005
Shire Pharmaceuticals Group plc (SHQ) and New River Pharmaceuticals Inc. (NRPH) announced the signing of an agreement for the global commercialization of NRP104, New River's phase 3 compound for treatment of attention deficit hyperactivity disorder (ADHD), as well as for other potential indications. Under the terms of the agreement the parties will collaborate on NRP104 development, manufacturing, marketing and sales in the U.S. Shire will book the product sales and New River may supply up to 25% of the sales effort under a co-promotion right. New River will be financially and operationally responsible for clinical and manufacturing development. Upon...
Source: Women's Health Weekly (2005-03-03)
|
